Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 10544 participants.

Also called NCT03071692

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 10,544 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03071692
Other papers using this trial's data
  • Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk The New England journal of medicine, 2022-11-24 DOI, PubMed 36342113

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Brazil, Bulgaria, Canada, Colombia, Czechia, Denmark, France, Germany, Hungary, India, Israel, Japan, Mexico, Netherlands, Poland, Puerto Rico, Romania, Russia, Slovakia, South Africa, Spain, Ukraine, United Kingdom (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT03071692. Randomized; quadruple masking; primary purpose prevention. Start 2017-03-23 (actual); primary completion 2022-07-27 (actual). Results posted on 2025-09-25.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)
Acronym
PROMINENT
Condition
Type2 Diabetes
Condition
Dyslipidemia
Intervention (Drug)
K-877
Intervention (Drug)
Placebo
Lead sponsor
Kowa Research Institute, Inc. (class: industry)
Collaborator
Brigham and Women's Hospital (class: other)

Record details

Record id
cardio:ct-nct03071692
Content hash
237abfeab941a1a7e993c75b8d99d30b20c1abf4b2adc985c5de144812f51edc